[Effectiveness of soluble rifampicin in combination with other antibacterial preparations in treating disseminated destructive pulmonary tuberculosis in an experiment].
Efficacy of a new rifampicin dosage form developed at the All-Union Research Institute of Antibiotics was studied on dogs with extensive destructive tuberculosis of the lungs. Intracavernous instillation and rapid intravenous administration (RIA) of the drug in combination with 10 per cent solution of isoniazid and intramuscular administration of streptomycin were used. Intracavernous instillation of rifampicin in combination with 10 per cent solution of isoniazid was performed under the control of an x-ray unit with an image converter tube or with the developed administration procedure through an indwelling catheter. Intracavernous administration of the drugs was alternated with their RIA: either one-stage administration of the antibiotic in daily half doses to each cavern followed by RIA every second day or RIA of a daily half dose in the morning followed by intracavernous instillation of the second half dose to one cavern in 5-6 hours and the second half dose to the other cavern on the next day. Intracavernous instillation of rifampicin in combination with isoniazid together with their RIA in treatment of extensive destructive tuberculosis of the lungs provided 100 per cent elimination of tubercle bacilli in the internal organs of all the dogs and closing of the caverns with cicatrization in 70 per cent of the dogs and formation of microcavities in 30 per cent of the dogs within 30 days.
Bondarev
I M
IM
Ivanov
V L
VL
Mozhokina
G N
GN
Novoselova
V P
VP
Kovaleva
L A
LA
D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D005260:Female; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007322:Instillation, Drug; D008297:Male; D012293:Rifampin / Q000008:administration & dosage*; D012995:Solubility; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D012293:Rifampin
Effektivnost' rastvorimogo rifampitsina v komplekse s drugimi antibakterial'nymi preparatami pri lechenii rasprostranennogo destruktivnogo tuberkuleza legkikh v éksperimente.